The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis

Current Rheumatology Reports

Volumn 8, Issue 4, 2006, Pages 255-259

  Elyan, Mazen ^a   Khan, Muhammad Asim ^b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIHISTAMINIC AGENT; ANTIRHEUMATIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E1 DERIVATIVE; PROTON PUMP INHIBITOR; ROFECOXIB; SUCRALFATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ANALGESIA; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; CARDIOTOXICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEADACHE; HEALTH PROGRAM; HUMAN; KINESIOTHERAPY; NAUSEA; PHYSIOTHERAPY; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; EXERCISE THERAPY; GASTROINTESTINAL DISEASES; HUMANS; SPONDYLITIS, ANKYLOSING;

EID: 33748426134     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0005-7     Document Type: Review

References (49)

1. Khan MA: Update on spondyloarthropathies. Ann Intern Med 2002, 135:896-907.
2. Boulos P, Dougados M, Macleod SM, Hunsche E: Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 2005, 65:2111-2127.
3. Zochling J, van der Heijde D, Dougados M, Braun J: Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2005, 65:423-432. The ASAS international working group, with funding from the EULAR, proposed ten recommendations for the management of AS management. These will be updated regularly.
4. Shekelle PG, Woolf SH, Eccles M, Grimshaw J: Clinical guidelines: developing guidelines. BMJ 1999, 318:593-596.
5. Dougados M, Dijkmanns B, Khan MA: Conventional treatment for ankylosing spondylitis. Ann Rheum Dis 2002, 61:40-50.
6. Toussirot E, Wendling D: Recent progress in ankylosing spondylitis treatment. Expert Opin Pharmacother 2003, 4:1-12.
7. Dougados M, Revel M, Khan MA: Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol 1998, 12:717-736.
8. Dougados M, Béhier JM, Jolchine I, Calin A, et al.: Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001, 44:180-185.
9. Chen J, Liu C: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004, 3:4524.
10. Van der Heijde D, Baraf HS, Ramos-Remus C, et al.: Arthritis Rheum. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005, 52:1205-1215.
11. Khan MA: Diclofenac in the treatment of ankylosing spondylitis: review of worldwide clinical experience and report of a double-blind comparison with indomethacin. Sem Arthritis Rheum 1985, 15:80-84.
12. Myklebust G: Comparison of naproxen and piroxicam in rheumatoid arthritis and Bechterew's syndrome. A double-blind parallel multicenter study. Tidsskr Nor Laegeforen 1986, 106:1485-1487.
13. Nahir AM, Scharf Y: A comparative study of diclofenac and sulindac in ankylosing spondylitis. Rheumatol Rehabilit 1980, 19:193-198.
14. Palferman TG, Webley M: A comparative study of nabumetone and indomethacin in ankylosing spondylitis. Eur J Rheumatol Inflamm 1991, 11:23-29.
15. Wasner C, Britton MC, Kraines RG, et al.: Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 1981, 246:2168-2172.
16. Zhang W, Doherty M, Arden N, et al.: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681.
17. Gossec L, van der Heijde D, Melian A, et al.: The efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005, 64:1563-1567.
18. Graham DY, Agrawal NM, Campbell DR, et al.: Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002, 162:169-175.
19. Hooper L, Brown TJ, Elliott R, et al.: The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004, 329:948.
20. Garcia Rodriguez LA: Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104:30S-34S.
21. Lewis SC, Langman MJ, Laporte JR, et al.: Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002, 54:320-326.
22. Decks JJ, Smith LA, Bradley MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002, 325:619-623.
23. Juni P, Nartey L, Reichenbach S, et al.: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364:2021-2029.
24. Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-481. This paper, based on data from Kaiser Permanente of California (Oakland, CA), has tried to clarify the controversy surrounding the question about whether high-dose rofecoxib increases or naproxen decreases the risk of serious coronary heart disease.
25. Bolten WW: Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2006, 65:7-13. A comprehensive review of the risk of atherothromobotic disease associated with the use of NSAIDs, both selective and nonselective.
26. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention Trial. N Engl J Med 2005, 352:1092-1102. A multicenter, randomized clinical trial, with a large number of participants (n = 2586), showed that among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
27. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080. A multicenter, randomized clinical trial with a large number of participants (n = 2035). Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure.
28. Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081-1091. A multicenter, randomized clinical trial, with a large number of participants (n = 1671). The use of parecoxib and valdecoxib after coronary artery bypass graft was associated with an increased incidence of cardiovascular events.
29. Zochling J, Bohl-Buhler MH, Baraliakos X, et al.: Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis-a population-based survey. Clin Rheumatol 2006, In press.
30. Wanders A, van der Heijde D, Landewe R, et al.: Inhibition of radiographic progression in ankylosing spondylitis (AS) by continuous use of NSAIDs. Arthritis Rheum 2005, 52:1756-1765. A well done study, which is the first to show a possible disease-modifying effect of continuous NSAIDs therapy in a prospective manner.
31. Ward MM: Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms? Arthritis and Rheum 2005, 52:1634-1636. An excellent, well-balanced review of the study by Wanders et al. [30•].
32. Beck A, Salem K, Krischak G, et al.: Nonsteroidal anti-inflammatory drugs (NSAIDs) in the perioperative phase in traumatology and orthopedics effects on bone healing. Oper Orthop Traumatol 2005, 17:569-578.
33. Mihai B, van der Linden S, de Bie R, Stucki G: Experts' beliefs on physiotherapy for patients with ankylosing spondylitis and assessment of their knowledge on published evidence in the field. Results of a questionnaire among international ASAS members. Eura Medicophys 2005, 41:149-153.
34. Dagfinrud H, Kvien TK, Hagen KB: The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol 2005, 32:1899-1906. This is an excellent update of the Cochrane review on the effectiveness of physiotherapy interventions in the management of AS.
35. van der Linden S, van Tubergen S, Hidding A: Physiotherapy in ankylosing spondylitis: what is the evidence? Clin Exp Rheumatol 2002, 20:S60-S64.
36. Kraag G, Stokes B, Groh J, et al.: The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis-a randomized controlled trial. J Rheumatol 1990, 17:228-233.
37. Kraag G, Stokes B, Groh J, et al.: The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis-an 8-month followup. J Rheumatol 1994, 21:261-263.
38. Hidding A, Van Der LS, Boers M, et al.: Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res 1993, 6:117-125.
39. Helliwell PS, Abbott CA, Chamberlain MA: A randomised trial of three different physiotherapy regimes in ankylosing spondylitis. Physiotherapy 1996, 82:85-90.
40. Analay Y, Ozcan E, Karan A, et al.: The effectiveness of intensive group exercise on patients with ankylosing spondylitis. Clinical Rehabilitation 2003, 17:631-636.
41. Sweeney S, Taylor G, Calin A: The effect of a home based exercise intervention package on outcome in ankylosing spondylitis: a randomized controlled trial. Journal of Rheumatology 2002, 29:763-766.
42. Lim HJ, Moon YI, Lee MS: Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int 2005, 25:225-29.
43. Bulstrode SJ, Barefoot J, Harrison RA, Clarke AK: The role of passive stretching in the treatment of ankylosing spondylitis. Br J Rheumatol. 1987, 26:40-42.
44. van Tubergen A, Landewe R, van der Heijde D, et al.: Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001, 45:430-438.
45. van Tubergen A, Boonen A, Landewe R, et al.: Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002, 47:459-467.
46. Heikkilä S, Viitanen JV, Kautiainen H, Kauppi M: Sensitivity to change of mobility tests; effect of short term intensive physiotherapy and exercise on spinal, hip, and shoulder measurements in spondyloarthropathy. J Rheumatol 2000, 27:1251-1256.
47. Uhrin Z, Kuzis S, Ward MM: Exercise and changes in health status in patients with ankylosing spondylitis. Arch Intern Med 2000, 160:2969-2975.
48. Lim HJ, Lee MS, Lim HS: Exercise, pain, perceived family support, and quality of life in Korean patients with ankylosing spondylitis. Psychol Rep 2005, 96:3-8.
49. Fernandez-de-Las-Penas C, Alonso-Blanco C, Morales-Cabezas M, Miangolarra-Page JC: Two exercise interventions for the management of patients with ankylosing spondylitis: a randomized controlled trial. Am J Phys Med Rehabil 2005, 84:407-419.